Pharmacokinetic Profile of Aprotinin (Trasylol®) in Female Patients Undergoing Primary Elective Hysterectomy

[1]  V. Boddi,et al.  High-dose aprotinin: hemostatic effects in open heart operations. , 1989, The Annals of thoracic surgery.

[2]  M. Jochum,et al.  REDUCTION OF HOMOLOGOUS BLOOD REQUIREMENT IN CARDIAC SURGERY USING HIGH DOSE APROTININ , 1989 .

[3]  G. Fraedrich,et al.  Reduction of Blood Transfusion Requirement in Open Heart Surgery by Administration of High Doses of Aprotinin - Preliminary Results , 1989, The Thoracic and cardiovascular surgeon.

[4]  D. Cosgrove,et al.  Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). , 1989, The Journal of thoracic and cardiovascular surgery.

[5]  W. Schleuning,et al.  Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. , 1989, Blood.

[6]  K. M. Taylor,et al.  EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.

[7]  W. van Oeveren,et al.  Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. , 1987, The Annals of thoracic surgery.

[8]  M. Silverberg,et al.  The coagulation-kinin pathway of human plasma , 1987 .

[9]  M. Jochum,et al.  Feasibility study of very high aprotinin dosage in polytrauma patients. , 1987, Progress in clinical and biological research.

[10]  H. Fritz,et al.  Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. , 1983, Arzneimittel-Forschung.

[11]  G. Sher.  Trasylol in the management of abruptio placentae with consumption coagulopathy and uterine inertia. , 1980, Journal of reproductive medicine.

[12]  E. Mammen.  NATURAL PROTEINASE INHIBITORS IN EXTRACORPOREAL CIRCULATION , 1968, Annals of the New York Academy of Sciences.

[13]  R. Clauss,et al.  HEMORRHAGE DUE TO FIBRINOLYSIS OCCURRING WITH OPEN-HEART OPERATIONS. , 1963, The Journal of thoracic and cardiovascular surgery.

[14]  H. Kraut,et al.  Über die Inaktivierung des Kallikreins. (VI. Mitteilung über dieses Kreislaufhormon.) , 1930 .